Outlook Therapeutics Inc. (OTLK)
Outlook Therapeutics Statistics
Share Statistics
Outlook Therapeutics has 32.62M shares outstanding. The number of shares has increased by 39.37% in one year.
| Shares Outstanding | 32.62M |
| Shares Change (YoY) | 39.37% |
| Shares Change (QoQ) | 30.98% |
| Owned by Institutions (%) | 17.72% |
| Shares Floating | 20.52M |
| Failed to Deliver (FTD) Shares | 30K |
| FTD / Avg. Volume | 5.23% |
Short Selling Information
The latest short interest is 3.5M, so 10.73% of the outstanding shares have been sold short.
| Short Interest | 3.5M |
| Short % of Shares Out | 10.73% |
| Short % of Float | 17.06% |
| Short Ratio (days to cover) | 5.92 |
Valuation Ratios
The PE ratio is -1.31 and the forward PE ratio is -1.65. Outlook Therapeutics's PEG ratio is -0.01.
| PE Ratio | -1.31 |
| Forward PE | -1.65 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Outlook Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.64, with a Debt / Equity ratio of 0.
| Current Ratio | 0.64 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.42 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.28M |
| Employee Count | 23 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -84.11% in the last 52 weeks. The beta is 0.47, so Outlook Therapeutics's price volatility has been higher than the market average.
| Beta | 0.47 |
| 52-Week Price Change | -84.11% |
| 50-Day Moving Average | 1.49 |
| 200-Day Moving Average | 4.32 |
| Relative Strength Index (RSI) | 51.64 |
| Average Volume (20 Days) | 573.11K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -71.7M |
| Net Income | -75.37M |
| EBITDA | -71.59M |
| EBIT | -71.7M |
| Earnings Per Share (EPS) | -9.84 |
Balance Sheet
The company has 14.93M in cash and 29.74M in debt, giving a net cash position of -14.81M.
| Cash & Cash Equivalents | 14.93M |
| Total Debt | 29.74M |
| Net Cash | -14.81M |
| Retained Earnings | -543,284.9B |
| Total Assets | 17,006.1B |
| Working Capital | -32,569.9B |
Cash Flow
In the last 12 months, operating cash flow was -68,793.9B and capital expenditures 0, giving a free cash flow of -68,793.9B.
| Operating Cash Flow | -68,793.9B |
| Capital Expenditures | 0 |
| Free Cash Flow | -68,793.9B |
| FCF Per Share | -3708801.1 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OTLK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for OTLK is $9, which is 547.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 547.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Mar 14, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Mar 14, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -45.59 |
| Piotroski F-Score | 0 |